A New Clinical Trial in KCNQ2-DEE and Upcoming Related Patient Survey

The KCNQ2 Cure Alliance has invited Dr. John Millichap, a Pediatric Epileptologist focused on KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE), and Dr. Simon Pimstone, CEO of Xenon Pharmaceuticals, to participate in this webinar.

Moderated by Caroline Loewy from the KCNQ2 Cure Alliance, topics will include:
• How mutations in the KCNQ2 gene for potassium channels in the brain are responsible for KCNQ2-DEE
• What we’ve learned to date from off-label use of Potiga®/Trobalt® as a treatment of pediatric KCNQ2-DEE
• Challenges of pediatric clinical trials in rare, genetic epilepsies
• Update on XEN496, a new pediatric formulation Potiga®/Trobalt® currently in development for KCNQ2-DEE
• Upcoming patient surveys and how this information will help shape future clinical trials
• Panel discussion, next steps, and ways to stay informed!

————————————————————————-
Dr. Millichap is a Pediatric Epileptologist in the Comprehensive Epilepsy Center, Ann & Robert H. Lurie Children’s Hospital of Chicago, and Associate Professor of Pediatrics and Neurology at Northwestern University Feinberg School of Medicine.

Dr. Simon Pimstone is the CEO of Xenon Pharmaceuticals, a company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions, with a particular focus on epilepsy.